Analysed VANDA PHARMACEUTICALS INC (VNDA:NASDAQ) News Sources
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
09-04-2026
yahoo.com
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists
08-04-2026
yahoo.com
AnaptysBio Board Approves Spin-Off of First Tracks Bio, Repurchase of $100 Million Shares
27-03-2026
yahoo.com
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods
19-03-2026
yahoo.com
Why Vanda Pharmaceuticals (VNDA) Is Up 17.4% After Rare FDA Hearing Granted On HETLIOZ Jet Lag
13-03-2026
yahoo.com
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
03-03-2026
yahoo.com
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
26-02-2026
yahoo.com
What is the current price of VANDA PHARMACEUTICALS INC (VNDA:NASDAQ)?
The current price of VANDA PHARMACEUTICALS INC (VNDA:NASDAQ) is $6.78.
VANDA PHARMACEUTICALS INC (VNDA:NASDAQ) absolute price change since previous trading day?
The absolute price change of VANDA PHARMACEUTICALS INC (VNDA:NASDAQ) since the previous trading day is $-0.21.
VANDA PHARMACEUTICALS INC (VNDA:NASDAQ) percentage price change since previous trading day?
The percentage price change of VANDA PHARMACEUTICALS INC (VNDA:NASDAQ) since the previous trading day is -3.0043%.
What is the most recent average sentiment score for VANDA PHARMACEUTICALS INC (VNDA:NASDAQ)?
The most recent average sentiment score for VANDA PHARMACEUTICALS INC (VNDA:NASDAQ) is 67 out of 100.
What is the most recent average sentiment for VANDA PHARMACEUTICALS INC (VNDA:NASDAQ)?
The most recent sentiment for VANDA PHARMACEUTICALS INC (VNDA:NASDAQ) is .
SEC-8K** Filing Available For VANDA PHARMACEUTICALS INC (VNDA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.